Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Treating the Acute NMOSD Attack: Stopping the Damage

At a Glance

An acute NMOSD attack is a medical emergency that requires immediate treatment to prevent permanent nerve damage. The standard treatment involves high-dose IV steroids and therapeutic plasma exchange (PLEX) to quickly stop the immune system's attack on the central nervous system.

When you are experiencing an NMOSD attack, time is your most precious resource. Because NMOSD is “attack-driven,” every hour that inflammation goes untreated increases the risk of permanent damage to your optic nerves or spinal cord [1][2]. Doctors treat these episodes as medical emergencies, with the goal of stopping the immune system’s attack as fast as humanly possible.

Step 1: High-Dose Steroids

The first line of defense for an acute attack is usually high-dose intravenous methylprednisolone (IVMP) [1][3].

  • The Dosage: You will typically receive 1,000 mg of steroids through an IV every day for 3 to 5 days [4].
  • The Goal: These “steroid pulses” work by quickly dampening the overall inflammation in your central nervous system [5].
  • The Reality: While steroids are a critical first step, they are only effective in about half of all NMOSD attacks [4]. For many patients, especially those with severe symptoms like vision loss or paralysis, steroids alone are not enough [6].

Step 2: Plasma Exchange (PLEX/TPE)

If steroids do not cause rapid improvement, or if the attack is severe from the start, the standard of care is Therapeutic Plasma Exchange (PLEX or TPE) [6][7].

  • How it Works: Think of PLEX as “washing your blood.” Your blood is cycled through a machine that separates the liquid part (plasma) from the blood cells. The machine removes your plasma—which contains the harmful AQP4 antibodies and “complement” proteins—and replaces it with healthy donor plasma or a protein solution (albumin) before returning it to your body [8][9].
  • Why Speed Matters: PLEX is most effective when started early. Research shows that patients who receive PLEX within the first few days of an attack have a much higher chance of regaining their vision or mobility than those who wait [10][11].
  • The “Rescue” Trap: In the past, doctors often waited to see if steroids worked before trying PLEX. Current medical consensus is shifting: waiting for steroids to “fail” can waste precious time [10][12]. For severe attacks, many experts now recommend starting PLEX immediately alongside steroids [10].

Step 3: Intravenous Immunoglobulin (IVIG)

If PLEX is not an option (due to poor vein access) or if additional support is needed, doctors may use Intravenous Immunoglobulin (IVIG). This treatment involves infusing high doses of healthy antibodies from blood donors to help neutralize the harmful NMOSD antibodies and reduce inflammation. It is a well-established rescue therapy that can be used alone or alongside steroids [13].

Why Speed is Critical

In NMOSD, the damage is caused by the complement system, which triggers severe inflammation and damage to the support cells of your nervous system [8]. Unlike some other conditions where you can wait and see, NMOSD damage can become permanent very quickly [1].

  • Early Treatment: Correlated with “favorable” clinical outcomes and the preservation of function [6][4].
  • Delayed Treatment: Associated with a lower probability of recovery and a higher risk of permanent disability [14][1].

Emerging Acute Options

While steroids and PLEX are the traditional “emergency room” tools, researchers are investigating whether newer medications can help during an attack. Some small studies suggest that eculizumab—a drug already FDA-approved as a preventative maintenance therapy—might help speed up recovery if given during the acute phase by instantly shutting down the complement system [15][16]. If you are in a major research hospital, you may want to ask if such options are available to you.

Common questions in this guide

What is the first treatment for an NMOSD attack?
The first line of defense is typically high-dose intravenous steroids, specifically methylprednisolone. This is usually given through an IV for three to five days to quickly reduce inflammation in the central nervous system.
What happens if steroids don't work for my NMOSD relapse?
If steroids do not rapidly improve your symptoms, doctors usually move to Therapeutic Plasma Exchange (PLEX). For severe attacks involving vision loss or paralysis, many experts now recommend starting PLEX immediately alongside steroids rather than waiting to see if steroids fail.
How does plasma exchange (PLEX) treat an NMOSD attack?
PLEX works by filtering your blood to remove the harmful plasma that contains NMOSD-causing antibodies and complement proteins. The machine replaces your plasma with healthy donor plasma or a protein solution before returning the blood to your body.
Why is fast treatment so important during an NMOSD flare?
NMOSD attacks cause severe inflammation that can rapidly lead to permanent damage in the optic nerves and spinal cord. Starting treatment like steroids or PLEX within the first few days significantly improves the chances of regaining vision and mobility.
Is IVIG used to treat acute NMOSD attacks?
Yes, Intravenous Immunoglobulin (IVIG) is used as a rescue therapy if plasma exchange is not an option, such as when a patient has poor vein access. It involves infusing healthy donor antibodies to help neutralize the harmful NMOSD antibodies and reduce inflammation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How quickly can we start high-dose IV steroids (methylprednisolone) and for how many days will I receive them?
  2. 2.Does this facility have the equipment and staff to perform Plasma Exchange (PLEX) if the steroids don't work quickly?
  3. 3.If my symptoms are severe (like vision loss or inability to walk), can we start PLEX simultaneously with steroids rather than waiting?
  4. 4.How will we measure whether the acute treatment is working, and at what point do we decide to 'escalate' the therapy?
  5. 5.Are there any emergency clinical trials or newer treatments like eculizumab available for acute management at this hospital?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment.

    Banerjee A, Ng J, Coleman J, et al.

    Multiple sclerosis and related disorders 2019; (28()):60-63 doi:10.1016/j.msard.2018.12.010.

    PMID: 30554039
  2. 2

    Two Cases of Very-Late-Onset Neuromyelitis Optica Spectrum Disorder (NMOSD) in Patients over the Age of 80.

    Fujiwara S, Manabe Y, Morihara R, et al.

    Case reports in neurology 2020; (12(1)):13-17 doi:10.1159/000505231.

    PMID: 32009931
  3. 3

    Immunobiology of neuromyelitis optica spectrum disorders.

    Mora Cuervo DL, Hansel G, Sato DK

    Current opinion in neurobiology 2022; (76()):102618 doi:10.1016/j.conb.2022.102618.

    PMID: 35973380
  4. 4

    Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD.

    Akaishi T, Takeshita T, Himori N, et al.

    Frontiers in neurology 2020; (11()):932 doi:10.3389/fneur.2020.00932.

    PMID: 33013632
  5. 5

    Autonomic Dysregulation, Cognitive Impairment, and Symptoms of Psychosis as an Unusual Presentation in an Anti-Aquaporin 4-Positive Patient.

    Ruiter AM, Meilof JF, Somanje-Bolweg RRJ, et al.

    Case reports in neurology 2017; (9(1)):12-16 doi:10.1159/000455942.

    PMID: 28413400
  6. 6

    PLEX: the best first-line treatment in nmosd attacks experience at a single center in Colombia.

    Restrepo-Aristizábal C, Giraldo LM, Giraldo YM, et al.

    Heliyon 2021; (7(4)):e06811 doi:10.1016/j.heliyon.2021.e06811.

    PMID: 33948520
  7. 7

    Visual Function Improvement after Plasma Exchange Therapy for Acute Optic Neuritis in Neuromyelitis Optica Spectrum Disorders: Case Series and Review.

    Iancu R, Pirvulescu R, Anton N, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(9)) doi:10.3390/diagnostics14090863.

    PMID: 38732279
  8. 8

    Endothelial cell-secreted SPARC suppresses astrocytic CD59 expression and promotes astrocytopathy in a mouse model of neuromyelitis optica spectrum disorders.

    Cui T, Gong Y, Wang Z, et al.

    Nature communications 2026; (17(1)).

    PMID: 42120878
  9. 9

    Effect of plasma exchange in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.

    Kosiyakul P, Songwisit S, Ungprasert P, et al.

    Annals of clinical and translational neurology 2020; (7(11)):2094-2102 doi:10.1002/acn3.51203.

    PMID: 32956562
  10. 10

    Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders.

    Bonnan M, Valentino R, Debeugny S, et al.

    Journal of neurology, neurosurgery, and psychiatry 2018; (89(4)):346-351 doi:10.1136/jnnp-2017-316286.

    PMID: 29030418
  11. 11

    Timing of plasma exchange for neuromyelitis optica spectrum disorders: A meta-analysis.

    Huang X, Wu J, Xiao Y, Zhang Y

    Multiple sclerosis and related disorders 2021; (48()):102709 doi:10.1016/j.msard.2020.102709.

    PMID: 33385827
  12. 12

    Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.

    Demuth S, Guillaume M, Bourre B, et al.

    Journal of neuroinflammation 2022; (19(1)):62 doi:10.1186/s12974-022-02420-2.

    PMID: 35236386
  13. 13

    Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.

    Pittock SJ, Zekeridou A, Weinshenker BG

    Nature reviews. Neurology 2021; (17(12)):759-773 doi:10.1038/s41582-021-00568-8.

    PMID: 34711906
  14. 14

    A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX.

    Songthammawat T, Srisupa-Olan T, Siritho S, et al.

    Multiple sclerosis and related disorders 2020; (38()):101506 doi:10.1016/j.msard.2019.101506.

    PMID: 31731214
  15. 15

    Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

    Rommer PS, Jiang W, Nolte JP, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2026; (13(2)):e200548 doi:10.1212/NXI.0000000000200548.

    PMID: 41671531
  16. 16

    Eculizumab as a rescue therapy in acute-phase aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder.

    Zeng K, Chen W, Lin A

    Journal of neurology 2026; (273(1)):73.

    PMID: 41511583

This page provides educational information about emergency treatments for NMOSD attacks and does not constitute medical advice. If you suspect you are experiencing an NMOSD attack, seek immediate emergency medical care.

Get notified when new evidence is published on Neuromyelitis optica spectrum disorder.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.